The company has agreed to pay Sanofi a 5% royalty on all revenues it generates from sales of the Unifill to other pharmas.until total product sales to other pharmas.reach 340mill. euros. The company has agreed to pay Sanofi 70% of any access,license or other upfront fee paid for access to purchase the Unifill product that Unilife may receive from other pharmas. until such time as total access fee revenue exceeds 14mill. euros. If access fee revenues exceed 14mill euros prior to 30th June 2014 then the company is required to pay Sanofi 30% of the access fee revenues it receives from that date until 30th June 2014........"the company expects that the commencement of product sales will coincide with the completion of the industrialisation program with Sanofi......."it is the ultimate responsibility of the pharma. company to obtain final FDA approval of the combination drug-delivery device" Just a bush lawyer, but i understand AMBIGUITY.
UNS Price at posting:
83.0¢ Sentiment: None Disclosure: Held
